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Background: This study was performed to test the hypothesis that a history of other
primary neoplasms before a lung cancer diagnosis increases the risk of subsequent
malignancy.
Methods: Of 8363 lung cancer patients seen from 1978 to 2002, 881 (11%) had at
least 1 previous nonlung primary malignancy. Charts were analyzed for the occur-
rence of subsequent malignancies.
Results: Lung cancer diagnosis in 881 patients consisted of 75% non–small cell,
12% small cell, and 13% other histologies. The median age was 66 years, with 56%
male, 76% white, and 86% smokers. Of the 881 patients, 92% had no subsequent
cancer (group 1), and 8% went on to experience the development of a new primary
neoplasm (including lung) after their lung cancer (group 2). After adequate follow-
up, the cumulative probability of developing a subsequent cancer did not differ
markedly between those with and without a prior non–lung cancer diagnosis at 2
years (12% vs 10%) or 5 years (16% vs 15%). Group 1 patients had a significantly
lower 1- and 5-year survival than group 2 patients (59% vs 48% and 29% vs 17%,
respectively; P .008). Although multivariate analysis suggested that stage, history
of tobacco-associated neoplasm, and history of definitive surgical resection were
important determinants in predicting long-term survival, a prior malignancy was not
an independent risk factor in the development of subsequent malignancy.
Conclusions: The risk of developing a subsequent malignancy is very high in lung
cancer patients with prior primary malignancies, but it is not markedly different
from the risks experienced by patients with no prior malignancies.
In the United States, lung cancer is the leading cause of cancer deaths in menand women and accounts for nearly one third of all cancer mortality.1 Withthe aging population and improvements in medical therapy, lung cancerpatients with a history of 1 or more previous primary tumors are presentingwith increasing frequency. Little is known about subsequent cancer risksand associations in these lung cancer patients with multiple independent
primaries (MIPs).
In this study, our primary objective was to evaluate the risk of development of
a subsequent (synchronous or metachronous) neoplasm in lung cancer patients with
previous malignancies. Our hypothesis was that lung cancer patients with MIPs had
an increased risk of subsequent cancers compared with lung cancer patients with no
previous malignancies. The published data suggest that the risk of developing a
second lung cancer in patients who survive a non–small-cell lung cancer is approx-
imately 1% to 2% per patient per year.2 For small-cell lung cancer, it is approxi-
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mately 6% per patient per year.2 For lung cancer patients
with previous malignancies, the rate of developing subse-
quent aerodigestive tract tumors has not been widely re-
ported.
Patients and Methods
From 1978 to 2002, 881 primary lung cancer patients with a
history of at least 1 malignancy in a site other than the lung
presented to the Johns Hopkins Hospital and made up our study
population. During the same period, 8005 lung cancer patients
with no history of malignancy presented to the same institution and
comprised our reference population. The study group was then
further subdivided into patients who had lung cancer as their last
cancer diagnosis and did not experience subsequent tumors (group
1; n  809) and patients who had additional neoplasms after their
primary lung cancer (group 2; n 72). All malignant cases entered
into the hospital’s cancer registry contain specific data on past
neoplasms to comply with internal requirements. Patients with
previous nonmelanoma skin cancers and diagnoses made at au-
topsy or at death were excluded from the study population. Ap-
proval to perform this study was obtained from the Institutional
Review Board of the Johns Hopkins Medical Institutions.
The number of multiple primary tumors in any case series can
vary greatly according to the definitions used, and strict local rules
were established to prevent misclassification of cancer metastases
to the lung as primary lung tumors. We defined multiple primary
tumors according to the National Cancer Database American Col-
lege of Surgeons’ rules to ensure consistent reproducibility be-
tween coders. Data collection guidelines for multiple primary
tumors were followed by using the Facility Oncology Registry
Data Standards developed by the American College of Surgeons.3
These standards define MIPs as 2 or more tumors arising at
different sites (defined by the first 3 digits of the International
Classification of Diseases for Oncology code)4 or at the same sites
when histologic characteristics differ. In cases of second tumors in
the lung, the question of whether the new lesion is a metastasis or
a second primary lung tumor is not always apparent. To avoid
misclassification, coders considered the criteria of Martini and
Melamed5 when classifying tumors of identical histology as mul-
tiple, independent lung primary tumors. In extreme cases, the
cancer registrar manager actively solicited the assistance of the
physician, the surgeon, and the pathologist for verification.
Both passive (via computer networks with national and re-
gional death/vital statistics data, as well as other hospital-based
registries) and active (telephone interviews) follow-up helped to
restrict losses to follow-up to less than 1% of total cases. Vital
status data were provided by the National Death Index of the
National Center Health Statistics for all study subjects not lost to
follow-up as of August 2002.
To compare the different patient groups, the 2 test of inde-
pendence was used for categorical variables, and the t test was
used for continuous variables. For analyses of cancer incidence,
each patient’s follow-up time was determined as the time from the
index lung cancer diagnosis to the first subsequent tumor or death,
loss to follow-up, or the end of the study period (Aug 31, 2002).
For analyses of survival, each patient’s follow-up time was deter-
mined as the time from the index lung cancer diagnosis to death,
loss to follow-up, or the end of the study period. We classified
cancer sites as tobacco associated and non–tobacco associated
according to the definition of the International Agency for Re-
search on Cancer.6 According to this definition, tobacco-associated
malignancies included cancers of the oral cavity and pharynx,
larynx, esophagus, lung, pancreas, stomach, bladder, kidney, liver,
and cervix. Malignancies from any other site were considered
non–tobacco associated.
The time from lung cancer diagnosis to subsequent cancer was
modeled by using the Kaplan-Meier method and was compared by
using the log-rank test for univariate analyses. Cox proportional
hazards models were fit to estimate the relative risks and 95%
confidence intervals associated with risks of subsequent cancer and
risks of death after adjustment for covariates. Stata statistical
software (Stata Corp, College Station, Tex) was used for all
analyses. All reported P values are 2 sided.
Results
The study population consisted of 881 patients with 1128
neoplasms: 952 prior cancers and 176 subsequent cancers.
The experience of prior and subsequent cancer diagnoses is
summarized in Table 1. The vast majority (85%) of all
patients had only a single prior malignancy. This proportion
did not differ between patients who did (83%) and did not
(85%) have a subsequent malignancy. Both the prior (30%;
284/952) and subsequent (44%; 78/176) neoplasms were
heavily weighted toward the tobacco-associated malignan-
cies—proportions that increased to 38% and 58%, respec-
tively, if only the tumors that presented immediately before
and after the lung cancer primary tumor were considered.
The 2- and 5-year cumulative probability of developing
a subsequent cancer diagnosis after lung cancer with a prior
non–lung cancer diagnosis was 12% and 16%, respectively
(Table 2). In comparison, the 2- and 5-year cumulative
probability of developing a subsequent cancer diagnosis
after lung cancer without a prior cancer diagnosis was 10%
and 15%, respectively (Table 2). A prior malignancy, there-
fore, is not an independent risk factor for developing sub-
sequent malignancies in lung cancer patients.
By univariate analysis, the patients in the study popula-
tion who had subsequent tumors after lung cancer (group 2)
TABLE 1. Distribution of subjects by prior and subsequent
cancer diagnoses (n  881)
Number of cancer
diagnoses before
first lung cancer
diagnosis
Number of cancer diagnoses after first lung
cancer diagnosis
0 1 2 3 Total
1 686* 52 5 3 746
2 107* 9 1 0 117
3 16* 2 0 0 18
Total 809* 63† 6† 3† 881
*Group 1.
†Group 2.
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were more likely than those who did not (group 1) to be
diagnosed with early-stage (stages I and II) disease of their
index lung tumor (P  .01) and were more likely to have
had a curative operation (P  .013; Table 3). Of the 278
patients with stage I and stage II disease, 11% went on to
have subsequent cancers, compared with 6% of the 504
patients with stage III and IV cancer (P  .01). The com-
parisons of patient demographics, smoking habits, occupa-
tional exposures, and tumor histology revealed no remark-
able differences between the 2 groups. When age, sex,
smoking habits, stage, surgical treatment, history of prior
tobacco-associated cancers, and tumor histology were si-
multaneously considered in a Cox proportional hazards
regression model, none of these was a significant predictor
of developing a subsequent tumor.
The median time from the most recent prior cancer
diagnosis to the onset of lung cancer was 58 months. The
median time for tobacco-associated tumors was 53 months,
versus 60 months for non–tobacco-associated malignancies
(Table 4). The median time to onset from the index lung
primary tumor to the next malignancy was 2.5 months
(Table 5). Of 72 patients who had a subsequent primary
malignancy, 44% (32/72) had another malignancy diag-
nosed at the same time as their primary lung tumor. The
probability of a subsequent malignancy developing syn-
chronously or metachronously in group 2 patients was 63%
(45/72) at 12 months and 74% (53/72) by 24 months.
By using the Cox model to analyze survival outcomes,
the data suggest that a patient’s stage, history of tobacco-
associated neoplasm, and history of definitive surgical re-
section were important determinants in predicting long-term
survival (Table 6). Figure 1 demonstrates that group 2
patients had an overall survival advantage over group 1
patients for both 1- and 5-year survival (48% vs 59% and
17% vs 29%, respectively; P  .008). In both groups, the
5-year survival data for stage 1 patients (45% and 48%,
respectively) were lower than published data for patients
presenting with lung cancer alone.
Discussion
Of 8363 lung cancer patients, 881 (11%) presented with a
history of at least 1 prior primary malignancy at our insti-
tution in more than 2 decades. A subsequent primary cancer
occurred in 8% (72/881). In this group of 72 patients, nearly
75% of patients had a new primary tumor within 2 years of
their lung cancer diagnosis. Not surprisingly for a study of
lung cancer patients, many of these new primary malignan-
cies were tobacco associated.
Factors associated with the primary tumor outcome (de-
velopment of subsequent malignancies) are complicated by
competing variables that predict death. Patients who are
current smokers, for example, would seem to be both more
likely to have another malignancy as well as to have short-
ened survival. The 72 patients in group 2 survived longer
than those with no subsequent cancer. By multivariate anal-
ysis, this prolonged survival in group 2 was associated with
a higher proportion of patients with early-stage lung cancers
that were amenable to curative surgical resection. A history
of a tobacco-associated malignancy was a risk factor for
shortened survival. By univariate analysis, tumor stage and
curative resection were associated with an increased risk of
subsequent malignancies. Even though the small number of
patients with a subsequent tumor (n  72) did not allow
these associations to withstand the rigors of statistical mod-
eling, our data suggest that variables associated with pro-
longed survival are also risk factors for subsequent disease.
This also suggests that the shared common etiologic expo-
sures of all 881 patients with MIPs in the study place them
at a very high risk for development of a subsequent malig-
nancy. For those who had prolonged survival (group 2), the
risk of another primary tumor developing within 2 years
was quite high but did not differ markedly from that of lung
cancer patients in general.
Few variables or measurement approaches exist that of-
fer predictive validity to those at risk for subsequent malig-
nancies. In this data set, patterns of organ-specific risks for
subsequent neoplasms suggest common etiologic factors,
TABLE 2. The cumulative probability of developing a subsequent malignancy after lung cancer by patients with a previous
nonlung malignancy (A; n  881) and patients with no previous malignancy (B; n  8005)
Time
(mo)
Individuals at risk Number of events
Number censored or
withdrawn
Cumulative
probability of
subsequent cancer
A B A B A B A B
0 881 8005 40 300 264 2895 .05 .05
6 577 4810 4 27 169 1623 .06 .06
12 404 3160 7 29 103 885 .08 .07
18 294 2246 2 22 67 458 .09 .08
24 225 1766 7 26 55 494 .12 .10
36 163 1246 4 23 33 268 .14 .12
48 126 955 2 8 27 166 .16 .13
60 97 781 0 13 16 109 .16 .15
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such as tobacco smoking, as critical factors in determining
patient outcome. Patients stratified as the highest risks were
those with a good prognosis for prolonged survival, such as
a non–small-cell lung cancer patient with early-stage resect-
able disease and a history of a non–tobacco-associated
tumor that occurred approximately 5 years previously. This
same phenomenon of prolonged survival being a risk factor
for subsequent disease has also been observed in popula-
tion-based studies. In reviewing 141,000 Swedish women
with breast cancer, Prochazka and associates7 found that
those at highest risk of a subsequent lung cancer were
TABLE 3. Characteristics of study population (n  881)
Characteristic
Group 1*
(n  809)
Group 2†
(n  72)
P valueNo. % No. %
Sex .892
Male 454 53 41 57
Female 355 44 31 43
Age, median (y) 66 — 66 — .686
Age (y)‡ .884
50 55 6.9 4 5.6
50–59 139 17.2 12 16.7
60–69 318 39.3 28 38.9
70–79 225 27.8 25 24.7
80 72 8.9 3 4.2
Race .907
White 613 76 55 76
Black/other 196 24 17 24
Marital status§ .989
Married 492 61.2 44 61.1
Not married 312 38.8 28 38.9
Smoking status .160
Never 117 14.5 7 9.7
Ever 692 85.5 65 90.3
Former 315 38.9 36 50.0
Current 377 46.6 29 40.3
Pack-years .271
Never 117 14.5 7 9.7
30 81 10.0 6 8.3
30–59 214 26.5 17 23.6
60–89 140 17.3 18 25.0
90 71 8.8 3 4.2
Unknown 186 23.0 21 29.2
Hazardous occupational exposure .511
Low 488 60.3 40 55.6
Moderate 112 13.8 9 12.5
High 101 12.5 11 15.3
Unknown 108 13.4 12 16.6
Histology .749
Adenocarcinoma 307 37.9 29 40.3
Squamous cell 227 28.1 22 30.6
Large cell 72 8.9 7 9.7
Small cell 98 12.1 5 6.9
Other 105 13 9 12.5
Stage .006¶
I 188 23.2 26 36.1
II 59 7.3 5 6.9
III 147 18.2 15 20.8
IV 328 40.5 14 19.4
Unknown 87 10.8 12 16.7
Definitive surgical treatment received .013
Yes 306 37.8 38 47.2
No 503 67.2 34 52.8
Time from prior diagnosis closest to first lung diagnosis (y) .615
0–1 115 14.2 12 16.7
1–2 107 13.2 6 8.3
196 24.2 19 26.4
2–5 196 24.2 19 26.4
5–10 180 22.3 13 18.1
10 211 26.1 22 30.6
Time to subsequent diagnosis (y) .458
0–1 — — 45 63
1–2 — — 8 11
TABLE 3. continued
Characteristic
Group 1*
(n  809)
Group 2†
(n  72)
P valueNo. % No. %
2–3 — — 8 11
3–4 — — 3 4
4–5 — — 2 3
6 — — 6 8
Tobacco-associated diagnoses of prior cancers .08
Tobacco
associated
266 32.9 31 43.1
Non–tobacco
associated
543 67.1 41 56.9
*Lung cancer diagnosis as the last diagnosis with at least 1 prior inde-
pendent cancer diagnosis.
†Lung cancer diagnosis with at least 1 prior independent cancer diagnosis
and with subsequent independent cancer diagnoses.
‡Age at first lung diagnosis.
§Married status available on only 804 patients.
Includes giant cell, in situ, basal cell, spindle cell, and other nonspecific
histologies.
¶P  .01; 2 test for independence.
TABLE 4. Median time for most recent prior diagnosis to
lung diagnosis (N  881)
Cancers N Median time (mo)
Total 881 58
Tobacco-associated 332 53
Oral cavity and pharynx 81 39
Larynx 77 55
Esophagus 8 7.5
Pancreas 6 99.5
Stomach 11 35
Bladder 66 45.5
Kidney 24 46.5
Liver 1 67
Cervix 58 136
549 60
Non-tobacco associated
Breast 108 68
Prostate 124 34.5
Colorectal 102 59.5
Other diagnoses 215 76
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women younger than 50 years old at the time of the breast
cancer diagnosis. Buiatti and associates8 found on analysis
of 19,000 incident cases of the breast, colon, rectum, lung,
and stomach in Italy that patients younger than 65 years old
were at a considerably higher risk of the development of
multiple cancers. In both of these studies, the effect of
increased medical surveillance as a part of patient follow-up
was speculated as a potential confounding factor.
The inclusion of information about cancers before lung
cancer in a study of this size with long-term follow-up
makes this study unique among investigations of subsequent
primary tumors after lung cancer. Despite its size, it is still
difficult in this study to discriminate precisely between
those patients at most risk for experiencing subsequent
malignancies and those who are not. Few studies have
examined this question of MIPs in primary lung cancer
patients, and most have been population-based and not
hospital-based registry analyses. Although the population-
based studies have methodologic advantages compared with
ours, our study provides excellent complementary evidence
because of the more specific clinical data on each patient.
Liu and colleagues9 showed in 193 Taiwanese patients
with MIPs involving the lung that cigarette smoking is a
significant risk factor (P  .001) for the development of
multiple malignancies. In their study, 26% (51/193) of lung
cancer patients had lung cancer as their first malignancy and
then subsequently experienced the development of a second
primary tumor, whereas the remaining 142 patients had a
history of malignancies antecedent to their lung cancer. In
agreement with our data, they observed a significant differ-
ence in the median time of onset of previous and subsequent
tumors to the index lung primary tumor (median, 46 vs 10
months, respectively, P  .001). After diagnosis and treat-
ment of a lung tumor, we also observed a shift of risk
toward neoplasms that were tobacco associated. Tobacco-
associated tumors represented only 32% of malignancies
that presented immediately before the lung diagnosis but
comprised 58% of subsequent tumors that presented imme-
diately after the lung cancer primary tumor. A second pri-
mary malignancy of the lung was the most common syn-
chronous and metachronous malignancy and occurred in
38% (27/72) of group 2 patients.
In this study, we did not limit our analysis to metachro-
nous malignancies that occurred after the primary lung
cancer diagnosis but included the risk of all subsequent
tumors. This introduces the possibility that confounding
factors such as overdiagnosis of occult tumors may have
biased these results. This effect of increased medical sur-
veillance can occur, for example, when a flurry of clinical
examinations is performed within the first month of a lung
cancer diagnosis to evaluate the behavior and extent of the
lung disease. Indeed, 44% of group 2 patients had other
primary tumors diagnosed synchronously with their lung
primary tumor, and in the first year, 63% had a subsequent
malignancy. The iatrogenic effect after treatment for the
first cancer and its effect on the incidence of any subsequent
malignancy was also not considered in our analysis. The
risk of lung cancer in women with previous breast cancer
who have undergone radiotherapy, for example, has been
shown to be significantly increased.7,8,10,11 In the future,
analysis of clonal differences between distinct lesions may
not only solve the current diagnostic dilemma between
multiple primary cancers and metastases, but also assist in
discerning the etiologic origins of MIPs from various organ
sites. Both van Rens and colleagues,12 using RNA muta-
tional analysis for p53, and Wang and colleagues,13 using
mutational analysis for p53 and K-ras codons 12 and 13,
demonstrated that molecular markers could distinguish the
independent origins of multiple tumors in the lung.
Figure 1. Survival curves of lung cancer patients with and with-
out subsequent diagnoses.
TABLE 5. Median time for most recent subsequent diag-
nosis (n  72)
Cancers No. Median time (mo)
Total 72 2.5
Tobacco associated 42 7
Lung 24 13.5
Oral cavity and pharynx 7 0
Larynx 2 0
Esophagus 2 0
Pancreas 2 11.5
Stomach 2 1.5
Bladder 2 119.5
Kidney 1 13
Liver — —
Cervix — —
30 0.5
Non–tobacco associated
Breast 6 0
Prostate 2 8.5
Colorectal 4 6.5
Other diagnoses 18 1.5
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In summary, this is one of the largest of only a few
investigations to report the incidence of subsequent neo-
plasms in lung cancer patients with previous malignancies.
There was no difference in the incidence of subsequent
malignancies in lung cancer patients if there was a previous
cancer. Factors associated with the development of a sub-
sequent malignancy are also those associated with longer
survival, such as early stage and curative resection. This
apparent increased risk likely reflects that these patients are
living longer and therefore have more opportunity for the
development of a subsequent cancer. We interpret this to
mean that all lung cancer patients with MIPs are at a high
risk for another primary tumor, especially within 2 years.
Many of these patients have received operative therapy and
often have their continued medical surveillance provided
exclusively by thoracic surgeons. Although there is no clear
consensus for postoperative follow-up, there is a growing
body of literature supporting the close monitoring of the
thorax, especially every 3 to 6 months for the first 2 years,
with radiologic imaging such as a chest radiograph or a
computed tomographic scan. This study supports this view
and underscores the importance of surgeons maintaining
vigilant follow-up, especially for tobacco-associated malig-
nancies, during the first 2 years after surgery.
We thank Kathy Bender for her technical assistance in helping
to prepare this manuscript.
References
1. Schottenfeld D. Etiology and epidemiology of lung cancer. In: Harvey
Pass JM, Johnson D, Turrisi A, Minna J, editors. Lung cancer. Phil-
adelphia: Lippincott Williams & Wilkins; 2000. p. 367.
2. Johnson BE. Second lung cancers in patients after treatment for an
initial lung cancer. J Natl Cancer Inst. 1998;90:1335-45.
3. The Facility Oncology Registry Data Standards (FORDS) (2002). Chi-
cago: Commission on Cancer, American College of Surgeons; 2002.
4. World Health Organization. International classification of diseases for
oncology. 3rd ed. Geneva: World Health Organization; 2000.
TABLE 6. Crude and adjusted risk estimates of mortality for patients with prior and subsequent diagnoses compared with
patients with prior but no subsequent cancer diagnosis (n  881)
Characteristic
Crude RR Adjusted RR*
RR 95% CI RR 95% CI
Sex
Female 1.0 Reference 1.0 Reference
Male 1.15 0.99–1.34 1.12 0.95–1.31
Age (y)
50 1.0 Reference 1.0 Reference
50–69 0.88 0.66–1.29 0.94 0.69–1.27
70 0.94 0.69–1.28 1.07 0.78–1.46
Smoking status
Never 1.0 Reference 1.0 Reference
Former 0.92 0.73–1.16 0.81 0.64–1.03
Current 1.27 1.01–1.58† 1.06 0.84–1.33
Histology
Adenocarcinoma 1.0 Reference 1.0 Reference
Squamous cell 1.22 1.01–1.46† 1.06 0.89–1.28
Large cell 1.15 0.88–1.51 1.04 0.79–1.36
Small cell 1.56 1.22–1.98‡ 0.96 0.75–1.23
Other§ 1.55 1.24–1.95‡ 1.14 0.90–1.43
Disease extent
Stage I 1.0 Reference 1.0 Reference
Stage II 1.69 1.23–2.34‡ 1.82 1.31–2.52‡
Stage III 2.05 1.60–2.63‡ 1.57 1.22–2.04‡
Stage IV 4.20 3.40–5.20‡ 2.73 2.16–3.45‡
Unknown 2.26 1.73–2.95‡ 1.39 1.05–1.85*
Tobacco association
Non–tobacco associated 1.0 Reference 1.0 Reference
Tobacco associated 1.18 0.99–1.32 1.25 1.09–1.50‡
Definitive surgical treatment received
No 3.37 2.86–4.00‡ 2.61 2.16–3.15‡
Yes 1.0 Reference 1.0 Reference
*Adjusted for age, sex, smoking status, cancer histology, stage, presence of tobacco-associated tumor, and surgical treatment.
†P  .05; ‡P  .01.
§Includes giant cell, non–small cell, in situ, basal cell, and other nonspecific histologies.
RR, Relative risk; 95% CI, 95% confidence interval.
General Thoracic Surgery Brock et al
1124 The Journal of Thoracic and Cardiovascular Surgery ● April 2004
G
TS
5. Martini N, Melamed MR. Multiple primary lung cancers. J Thorac
Cardiovasc Surg. 1975;70:606-12.
6. IARC Monograph: Tobacco and Involuntary Smoking (June 2002).
Volume 83. Lyon, France: IARC Press, International Agency for
Research on Cancer; 2002.
7. Prochazka M, Granath F, Ekbom A, et al. Lung cancer risks in women
with previous breast cancer. Eur J Cancer. 2002;38:1520-5.
8. Buiatti E, Crocetti E, Acciai S, et al. Incidence of second primary
cancers in three Italian population-based cancer registries. Eur J Can-
cer. 1997;33:1829-34.
9. Liu YY, Chen YM, Yen SH, et al. Multiple primary malignancies
involving lung cancer—clinical characteristics and prognosis. Lung
Cancer. 2002;35:189-94.
10. Inskip PD, Boice JD Jr. Radiotherapy-induced lung cancer among
women who smoke. Cancer. 1994;73:1541-3.
11. Neugut AI, Robinson E, Lee WC, et al. Lung cancer after radiation
therapy for breast cancer. Cancer. 1993;71:3054-7.
12. van Rens MT, Eijken EJ, Elbers JR, et al. p53 mutation analysis for
definite diagnosis of multiple primary lung carcinoma. Cancer. 2002;
94:188-96.
13. Wang X, Christiani DC, Mark EJ, et al. Carcinogen exposure, p53
alteration, and K-ras mutation in synchronous multiple primary lung
carcinoma. Cancer. 1999;85:1734-9.
Discussion
Dr Joe B. Putnam, Jr (Houston, Tex). The authors present
their detailed and carefully analyzed experience with lung cancer
in association with a second primary malignancy. The authors
appropriately expand upon the information presented by the Lung
Cancer Study Group, Thomas and colleagues, in 1993, where 55
patients with long-term survival developed a cancer and 13 were
nonpulmonary cancers, and also confirmed the work presented by
Rice and colleagues from our institution at the recent meeting of
the Society of Thoracic Surgeons.
The authors suggest that the development of subsequent ma-
lignancies is sufficiently high to warrant specific consideration by
the physician. Routine post–cancer resection screening for neo-
plasms may take place with a simple office visit and chest radio-
graph or more intensive screening procedures. What is the recom-
mendation for follow-up in these patients? There has been
considerable controversy as to the value of follow-up in patients
with lung cancer, specifically regarding its cost-effectiveness and
ability to improve overall survival. Screening for cancer in all
patients with prior malignancies would be prohibitively expensive.
In both groups, 90% to 95% were either former or current
smokers. Nearly half the patients in group 1 and 40% of patients
in group 2 were current smokers. Were these patients counseled
and assisted to quit smoking?
I know that you plan further evaluation of the biological char-
acteristics of these tumors, but how can you help us today? Are
there any specific anatomic or histologic characteristics that would
predispose patients to develop subsequent malignancies and
screening for subsequent treatment?
In summary, patients who undergo curative resection of malig-
nancies are at risk for developing subsequent malignancies. Eval-
uation by a thoracic surgeon should include questions and exam-
inations to screen for the subsequent neoplasms. Continuity of care
and appropriate screening technology will be needed to optimize
care and improve survival for these patients at increased risk of
developing subsequent malignancy.
Dr Brock. I thank Dr Putnam very much for his comments and
his analysis. Regarding the first question about the recommenda-
tions for screening, I do think that it is imperative that all of these
patients be screened. Since our study looked primarily at lung
cancer patients with previous malignancies, I think our data sug-
gest that these patients are at an extremely high risk for developing
new aerodigestive tract tumors. Interestingly, a quarter of all the
patients who had subsequent aerodigestive tract tumors actually
had a synchronous diagnosis with their lung cancer primary.
I think in follow-up, at the very least, a chest radiograph is
warranted every 3 to 6 months for the first 2 years. Maybe some of
these data, along with the data that were presented at the Society
of Thoracic Surgeons by Dr Rice from your institution, can be the
basis for future clinical trials to evaluate the role of high-resolution
computed tomographic scans, or even positron emission tomogra-
phy scans, in the follow-up of postoperative patients with lung
cancer. If a study such as this is performed, it is imperative that
surgeons take a critical and pivotal role in conducting these trials
because of their crucial role in the day-to-day follow-up care of
these patients.
As for your second question regarding the high degree of
smoking in this population and smoking counseling, this was
largely, as you know, a cancer registry study. Consequently, there
was not a large-scale counseling effort to individual patients. We
have, however, routinely counseled patients individually, espe-
cially after surgery. We also have launched new smoking aware-
ness programs in the institution, but these have been rather limited
in scale and generally involved only 1 or 2 medical departments.
I think that as we begin to understand even more the long-term
effects of cigarette smoking, having an institutional-wide program
is going to be even more imperative.
As far as biological characteristics or molecular profiling of
these tumors, we are actually in the process of looking at that from
both a genetic and an epigenetic standpoint. I think that this is
exciting, especially looking at the epigenetic possibilities, because
of the translational potential of this exciting biomarker.
We did perform a multivariate analysis to see whether we could
identify patterns of histologic or anatomic associations that may
predispose patients to develop subsequent malignancies, and un-
fortunately, this proved to be disappointingly negative. Although
this was a large study, only 72 patients developed subsequent
tumors, and I think to answer your question adequately about the
patterns of risk, we probably need to have an even larger group of
patients who develop subsequent malignancies for our confidence
intervals to remain narrow.
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